5N Plus acquires MCP Group
5N Plus deploys a range of proprietary and technologies to produce products which are used in a number of pharmaceutical, electronic and industrial applications. Following the acquisition, MCP
South Korea-based Alteogen has signed an exclusive licensing deal worth up to $365m with a global pharmaceutical company, granting worldwide rights to develop and commercialise a subcutaneous biologic product using its Hybrozyme technology.